Literature DB >> 31098991

siRNA Library Screening to Identify Complementary Therapeutic Pairs in Triple-Negative Breast Cancer Cells.

Bindu Thapa1, K C Remant2, Hasan Uludağ3,4,5.   

Abstract

The existence of tightly integrated cross talk through multiple signaling and effector pathways has been appreciated in malignant cells. The realization of the plasticity of such networks is stimulating the development of combinational therapy to overcome the limitations of one-dimensional therapies. Synergistic pairs of siRNAs or siRNA and drug combinations are the new frontiers in identifying effective therapeutic combinations. To elucidate effective combinations, we developed a versatile protocol to screen siRNA libraries in triple-negative breast cancer cell models. This protocol outlines the steps to identify synergistic combinations of siRNA-siRNA or siRNA-drug combinations using siRNA libraries via a robotic screen. By focusing on smaller functional siRNA libraries, we present methodologies to identify synergistic siRNA pairings against cancerous cell growth and molecular targets to augment the activity of pro-apoptotic TRAIL protein. Here, we summarize the critical steps to undertake such combinational target identification, emphasizing critical factors that affect the outcome of the screens. Our experience suggests that siRNA library screening is an efficient protocol to identify complementary therapeutic pairs of new or already-existing drugs. This protocol is simple, robust and can be completed within a 1-week working period.

Entities:  

Keywords:  Triple-negative breast cancer cells; siRNA library screening; siRNA transfection

Mesh:

Substances:

Year:  2019        PMID: 31098991     DOI: 10.1007/978-1-4939-9220-1_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

1.  Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes.

Authors:  Tinnabhop Santadkha; Wanwisa Skolpap; Remant K C; Aysha Ansari; Cezary Kucharski; Teo Atz Dick; Hasan Uludağ
Journal:  Invest New Drugs       Date:  2022-07-14       Impact factor: 3.651

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.